Jupiter Neurosciences Secures $100M Term Sheet for ALA-002 MDMA U.S. Rights
JUNS•Jupiter Neurosciences agreed to pay $3.33 million upfront and issue $1.83 million in stock for exclusive U.S. rights to ALA-002, plus milestone payments and royalties, closing in 90 days. ALA-002 is a patented non-racemic MDMA NCE engineered to enhance cardiovascular safety and reduce abuse liability in a $6–15 billion psychedelic therapeutics market.
1. Exclusive Licensing Agreement
Jupiter Neurosciences entered a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002 for $3.33 million upfront (split $1.5 million cash and $1.83 million stock), plus milestone payments and single-digit royalties. A $600,000 escrow deposit is credited to the upfront cash, with closing scheduled within 90 days and reverse termination provisions if the definitive agreement is not executed.
2. ALA-002 Drug Profile
ALA-002 is a patented, non-racemic MDMA novel chemical entity engineered to improve cardiovascular safety and reduce abuse liability while preserving the pro-social and therapeutic properties central to MDMA-assisted therapy. The formulation has FDA NCE recognition and is supported by active government-sponsored VA and DHA clinical trials, highlighting its potential in treating PTSD, anxiety, and neuropsychiatric conditions.
3. Regulatory Catalysts and Market Outlook
An April 18, 2026 Executive Order directs FDA and DEA to expand access to investigational psychedelic therapies through Right to Try pathways, priority vouchers, and $50 million ARPA-H funding. Analysts forecast the regulated psychedelic therapeutics market to reach $6–15 billion in annual sales by the early 2030s, driven by MDMA-assisted treatments for depression, PTSD, and anxiety disorders.
